Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment

24 February 2023 – the FDA published draft guidance on developing drugs for treating neovascular age-related macular degeneration. Submit comments by 30 May 2023.

This guidance is intended to provide recommendations to sponsors regarding eligibility criteria, trial design considerations, and efficacy endpoints to enhance clinical trial data quality and to foster greater efficiency in development programs for drugs for the treatment of neovascular age-related macular degeneration.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /